EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudieOpen Access · CC BY 4.0

Multicenter validation of secondary hemophagocytic lymphohistiocytosis diagnostic criteria

Gunnar Lachmann iD, Patrick Heeren, Friederike S Schuster, Peter Nyvlt, Claudia Spies, Insa Feinkohl, Thomas Schenk, Wafa Ammouri, France Debaugnies, Lionel Galicier, Yuan Jia, Nikhil Meena und 12 weitere

Journal of Internal Medicine · 2025-03 · 297 (3) · 312-327

DOI: 10.1111/joim.20065 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Internal Medicine, online erschienen am 27.01.2025. Verfasst von Gunnar Lachmann und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Intensive Care Medicine (CCM, CVK), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin…. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité - Universitätsmedizin Berlin, Charité – Universitätsmedizin Berlin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Five fulfilled hemophagocytic lymphohistiocytosis (HLH)‐2004 criteria, and the HScore are widely used and recommended by international expert consensus to diagnose secondary HLH. Both diagnostic scores have never been validated in heterogeneous patient cohorts of secondary HLH patients. We aimed to systematically optimize and validate diagnostic criteria of secondary HLH using a multicenter approach.

Methods

We developed optimized criteria in our cohort of critically ill patients as a first step. We next validated these new criteria together with the original and modified HLH‐2004 criteria as well as the HScore using original data of 13 published cohorts, which were identified by a systematic literature search.

Results

The best performing HLH diagnostic criteria sets over all 13 validation cohorts were the original HLH‐2004 criteria with a decreased cut‐off (cut‐off 4, mean sensitivity 86.5%, mean specificity 86.1%), followed by the revised HLH‐2004 criteria (natural killer cell activity removed; cut‐off 4, mean sensitivity 83.8%, mean specificity 87.8%) and the HScore (cut‐off 169, mean sensitivity 82.4%, mean specificity 87.6%). Our newly developed HLH diagnostic criteria showed inferior performance. Ferritin ≥500 µg/L had 94.0% mean sensitivity over all cohorts.

Conclusions

In this first multicenter validation study, four fulfilled HLH‐2004 criteria and an HScore of 169 were suitable to diagnose secondary HLH, which will lead to rapid diagnosis and improved patient outcomes. Ferritin proved as a reliable HLH screening marker. Our results should be taken into account in clinical recommendations and in designing new studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphohistiocytosis, HemophagocyticHumansFerritinsMaleFemaleSensitivity and SpecificityMiddle AgedAdultAged

Stichwörter der Autor:innen

HLH‐2004 criteriaHScorehemophagocytic lymphohistiocytosis (HLH)hemophagocytic syndrome (HPS)macrophage activation syndrome (MAS)validation

Substanzen

Ferritins

Autor:innen und Institutionen

  • Department of Anesthesiology and Intensive Care Medicine (CCM, CVK), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Institute of Medical Informatics, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Medical Biometry and Epidemiology Group, Witten/Herdecke University, Witten, Germany.
  • Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC), Molecular Epidemiology Research Group, Berlin, Germany.
  • Department of Hematology and Oncology, Universitätsklinikum Jena, Jena, Germany.

ORCID-Profile: Gunnar Lachmann, Cornelia Lachmann

Förderung

  • Charité - Universitätsmedizin Berlin
  • Charité – Universitätsmedizin Berlin

Zitieren

APA

Lachmann, G., Heeren, P., Schuster, F. S., Nyvlt, P., Spies, C., Feinkohl, I., Schenk, T., Ammouri, W., Debaugnies, F., Galicier, L., Jia, Y., Meena, N., Nagant, C., Neth, O., Nierkens, S., San Martin, J., Sun, H. W. L., Wang, Y., Wang, Z., …, & Lachmann, C. (2025). Multicenter validation of secondary hemophagocytic lymphohistiocytosis diagnostic criteria. Journal of Internal Medicine, 297(3), 312-327. https://doi.org/10.1111/joim.20065

Vancouver

Lachmann G, Heeren P, Schuster FS, Nyvlt P, Spies C, Feinkohl I, et al. Multicenter validation of secondary hemophagocytic lymphohistiocytosis diagnostic criteria. Journal of Internal Medicine. 2025;297(3):312-327. doi:10.1111/joim.20065

BibTeX
@article{Lachmann2025,
  author = {Lachmann, Gunnar and Heeren, Patrick and Schuster, Friederike S and Nyvlt, Peter and Spies, Claudia and Feinkohl, Insa and Schenk, Thomas and Ammouri, Wafa and Debaugnies, France and Galicier, Lionel and Jia, Yuan and Meena, Nikhil and Nagant, Carole and Neth, Olaf and Nierkens, Stefan and San Martin, Juan and Sun, Hao Wei Linda and Wang, Yini and Wang, Zhao and Yoon, Jae-Ho and Brunkhorst, Frank M and La Rosée, Paul and Janka, Gritta and Lachmann, Cornelia},
  title = {Multicenter validation of secondary hemophagocytic lymphohistiocytosis diagnostic criteria},
  journal = {Journal of Internal Medicine},
  year = {2025},
  volume = {297},
  number = {3},
  pages = {312--327},
  doi = {10.1111/joim.20065}
}
Kostenlos starten →